Literature DB >> 18407457

Current approaches in the treatment of Alzheimer's disease.

Reena S Shah1, Hyoung-Gon Lee, Zhu Xiongwei, George Perry, Mark A Smith, Rudy J Castellani.   

Abstract

The management of Alzheimer's disease (AD) has been a long-standing challenge and area of interest. Advances in knowledge of the pathogenesis of disease and an increase in disease burden have prompted investigation into innovative therapeutics over the last two decades. This article reviews the various treatments of AD including those targeted towards cholinergic deficiency, oxidative stress, the amyloid cascade, inflammation, and excitotoxicity. Second generation cholinesterase inhibitors remain the preferred therapy for early and intermediate AD while the glutamate antagonist, memantine, is also approved for advanced stages of disease. Antioxidants may delay disease progression, while data on other experimental therapies remain equivocal at best. Gene therapy directed at neurotropins is currently under investigation with some intriguing preliminary results; however, the number of patients examined is too few to be conclusive. Drugs directly targeting amyloid-beta, particularly the amyloid-beta vaccine, continue to be investigated and their forthcoming results are eagerly anticipated.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18407457     DOI: 10.1016/j.biopha.2008.02.005

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  37 in total

1.  Therapy for Alzheimer's Disease: How Effective are Current Treatments?

Authors:  Krista L Lanctôt; Ryan D Rajaram; Nathan Herrmann
Journal:  Ther Adv Neurol Disord       Date:  2009-05       Impact factor: 6.570

Review 2.  Deregulated Cdk5 activity is involved in inducing Alzheimer's disease.

Authors:  Varsha Shukla; Susan Skuntz; Harish C Pant
Journal:  Arch Med Res       Date:  2012-11-07       Impact factor: 2.235

3.  Intravenous ascorbate improves spatial memory in middle-aged APP/PSEN1 and wild type mice.

Authors:  John A Kennard; Fiona E Harrison
Journal:  Behav Brain Res       Date:  2014-02-05       Impact factor: 3.332

Review 4.  Mitochondria, cholesterol and amyloid beta peptide: a dangerous trio in Alzheimer disease.

Authors:  Anna Colell; Anna Fernández; José C Fernández-Checa
Journal:  J Bioenerg Biomembr       Date:  2009-10       Impact factor: 2.945

5.  New lobane and cembrane diterpenes from two comorian soft corals.

Authors:  Isabelle Bonnard; Sabina B Jhaumeer-Laulloo; Nataly Bontemps; Bernard Banaigs; Maurice Aknin
Journal:  Mar Drugs       Date:  2010-02-23       Impact factor: 5.118

6.  Altered effective connectivity patterns of the default mode network in Alzheimer's disease: an fMRI study.

Authors:  Yufang Zhong; Liyu Huang; Suping Cai; Yun Zhang; Karen M von Deneen; Aifeng Ren; Junchan Ren
Journal:  Neurosci Lett       Date:  2014-07-01       Impact factor: 3.046

7.  Synthesis, pharmacological assessment, and molecular modeling of acetylcholinesterase/butyrylcholinesterase inhibitors: effect against amyloid-β-induced neurotoxicity.

Authors:  Daniel Silva; Mourad Chioua; Abdelouahid Samadi; Paula Agostinho; Pedro Garção; Rocío Lajarín-Cuesta; Cristobal de Los Ríos; Isabel Iriepa; Ignacio Moraleda; Laura Gonzalez-Lafuente; Eduarda Mendes; Concepción Pérez; María Isabel Rodríguez-Franco; José Marco-Contelles; M Carmo Carreiras
Journal:  ACS Chem Neurosci       Date:  2013-02-04       Impact factor: 4.418

8.  Administration of memantine during withdrawal mitigates overactivity and spatial learning impairments associated with neonatal alcohol exposure in rats.

Authors:  Nirelia M Idrus; Nancy N H McGough; Edward P Riley; Jennifer D Thomas
Journal:  Alcohol Clin Exp Res       Date:  2014-01-15       Impact factor: 3.455

9.  Vitamin C reduces spatial learning deficits in middle-aged and very old APP/PSEN1 transgenic and wild-type mice.

Authors:  F E Harrison; A H Hosseini; M P McDonald; J M May
Journal:  Pharmacol Biochem Behav       Date:  2009-06-17       Impact factor: 3.533

10.  Activation of muscarinic receptors inhibits glutamate-induced GSK-3β overactivation in PC12 cells.

Authors:  Ke Ma; Li-min Yang; Hong-zhuan Chen; Yang Lu
Journal:  Acta Pharmacol Sin       Date:  2013-05-20       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.